摘要:
The invention pertains to triazolopurines of formula (I). The claimed compounds show an affinity to adenosine receptors and thus represent a new class of adenosine antagonists. Generally, adenosine antagonists can have a therapeutically useful effect in cases where diseases or pathological situations involve activation of adenosine receptors.
摘要:
The invention pertains to triazolopurines of formula (I). The claimed compounds show an affinity to adenosine receptors and thus represent a new class of adenosine antagonists. Generally, adenosine antagonists can have a therapeutically useful effect in cases where diseases or pathological situations involve activation of adenosine receptors.
摘要:
The present invention relates to new imidazotriazolopyrimidine derivatives of general formula (I), to methods for preparing the same and to their use as a drug. In this formula, the interrupted lines between nitrogen atoms represent a double link in one of two possible positions so that the radicals R?4 and R6 or R3 and R2¿ cannot be present simultaneously, wherein the radicals R1 to R6 are such as described in the description and the claims.
摘要:
The present invention relates to new imidazotriazolopyrimidine derivatives of general formula (I), to methods for preparing the same and to their use as a drug. In this formula, the interrupted lines between nitrogen atoms represent a double link in one of two possible positions so that the radicals R?4 and R6 or R3 and R2¿ cannot be present simultaneously, wherein the radicals R1 to R6 are such as described in the description and the claims.
摘要:
The invention relates to novel asymmetrically substituted xanthine derivatives of general formula (I), to methods for producing them and to their use as medicaments with an adenosine-antagonistic effect. The broken line between the nitrogen atoms of the general formula (I) indicates the existence of a double bond in one of two possible positions so that the radicals R?4 and R5¿ cannot be present at the same time. R1 cannot have the meaning of R2 at the same time. The radicals R?1, R2, R3, R4 and R5¿ are defined as follows: R1 is hydrogen, C¿1?-C6 alkyl, C3-C6 alkenyl or C3-C6 alkinyl; R?2¿ is a C¿1?-C6 alkyl, C3-C6 alkenyl or C3-C6 alkinyl radical which is substituted by -OR?6, -SO¿2R?6, -OCOR9, -COOR9, -NR7R8¿, -OCH¿2?CH2-NR?7R8, -CONR7R8¿, -OCH¿2?-CONR?7R8¿ or OCH¿2?CH2-CONR?7R8; R2¿ is a C¿1?-C6 alkyl, C3-C6 alkenyl or C3-C6 alkinyl radical which is substituted by a C-bonded 5 or 6-membered heterocyclic ring which may contain 1, 2, 3 or 4 heteroatoms selected from the following group: oxygen, nitrogen or sulphur; and may optionally be substituted by C1-C4 alkyl or benzyl; R?3 is C¿1-C6 alkyl which can be substituted by OH or optionally, norbornanyl, norbornenyl, adamantyl or noradamantyl substituted by methyl or OH and R4 or R5 is hydrogen, benzyl or benzyl substituted once, twice or three times by methoxy. R6 can mean hydrogen, C¿3?-C6 cycloalkyl or C1-C4 alkyl which may be substituted by -OR?9¿ or -OCOR9, R7 can mean hydrogen, -SO¿2R?6, C1-C4 alkyl, -COR9 or -COOR9; R8 can mean hydrogen, -SO¿2R?6, C1-C4 alkyl, -COR9 or -COOR?9 or R7 and R8¿ can form a 5 or 6-membered ring together with the nitrogen, whereby said ring may contain oxygen or nitrogen as a further heteroatom and may optionally be substituted by C¿1?-C4 alkyl or benzyl; and R?9¿ can mean hydrogen or C¿1?-C4 alkyl, optionally in the form of their racemates, their enantiomers, their diastereomers and their mixtures, and optionally in the form of their pharmacologically safe acid addition salts.
摘要:
The present invention relates to novel pharmaceutical compositions based on steroids and salts of a new anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints.
摘要:
The present invention relates to novel pharmaceutical compositions based on beta2 agonists and salts of a new anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints, wherein the anticholinergic agent has the formula (I).
摘要:
The invention relates to the use of selected EGFR kinase inhibitors, especially selected quinazolines, quinolines, and pyrimidopyrimidines, for treating nasal polyposis and chronic rhinosinusitis.
摘要:
The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors and salts of a new anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints.